Industry Use of Abbreviated 510(k) Falling Short of Agency Expectations
This article was originally published in The Gray Sheet
Executive SummaryIndustry fears over the possibility of automatic inspections of companies electing to follow the abbreviated 510(k) approval path are unfounded, FDA staffers maintain.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.